DekaBank Deutsche Girozentrale
STML

DekaBank Deutsche Girozentrale’s Stemline Therapeutics, Inc. STML Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,600
Closed -$246K – 1257
2018
Q1 		$246K Buy
+15,600
New +$243K ﹤0.01% 966

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

DekaBank Deutsche Girozentrale's STML Position: Q2 2018 in Review

DekaBank Deutsche Girozentrale sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 15,600 shares — an estimated $246K sold.

DekaBank Deutsche Girozentrale first reported a position in STML in Q1 2018 and held it in 1 quarter. The position peaked at $246K in Q1 2018. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

  • DekaBank Deutsche Girozentrale reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 15,600 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $246K.
  • DekaBank Deutsche Girozentrale first reported a position in Stemline Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
  • DekaBank Deutsche Girozentrale's Stemline Therapeutics, Inc. position peaked at $246K in Q1 2018.
  • 91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2018, filed 14 Aug 2018.